The cell-free protein expression market size is estimated to be USD 284.71 million in 2022 and is expected to witness a CAGR of 8.65% during the forecast period 2023-2033. Rising genomics and proteomics research and development, increasing prevalence of chronic diseases such as diabetes, cancer, cardiovascular disease, and others, structural modification and reduced expression time requirements for CFPE are factors contributing to the market growth. Additionally, surging major players’ marketing initiatives to spread the knowledge about improvements in their cell-free protein expression systems is predicted to support the market growth. However, absence of efficient post-translational modification methods and high price of protein expression systems is expected to hinder the growth.

Increasing prevalence of chronic diseases such as diabetes, cancer, cardiovascular disease, and others is projected to fuel the market growth. For instance, it is anticipated that 537 million adults (20-79 years) worldwide had diabetes in 2021, according to data from the International Diabetes Federation (IDF) Diabetes Atlas Tenth Edition 2021, which was published in December 2021. The same source predicts that by 2030, there will be 643 million cases of diabetes worldwide, and by 2045, there will be 783 million cases.

Surging major players’ marketing initiatives to spread the knowledge about improvements in their cell-free protein expression systems is expected to propel the market growth For instance, Codex DNA, Inc., a synthetic biology company with headquarters in the United States, announced on June 1, 2022, that it would demonstrate its BioXp system and RapidAMP technology for workflows for engineering antibodies and proteins at the Antibody Engineering and Therapeutics Europe Conference, which would take place from June 7 to 9, 2022. In a single run, the BioXp system offers hands-free, complete automation of DNA assembly, cloning, amplification, and mRNA synthesis.

Segmentation

By Product

The market is categorized into reagents and expression systems. The expression systems is further segmented into wheat germ cell-free protein expression system, e. coli cell-free protein expression system, insect cells cell-free protein expression system, human cell-free protein expression system, rabbit reticulocytes cell-free protein expression system, and others. In the global market, the e. coli cell-free protein expression system segment accounted for the largest revenue share in 2022 owing to their affordability and increasing protein output. E. coli lysates are among the most popular lysates in the commercial world. Recombinant technology also uses E. coli-based systems for a variety of biological therapies, including insulin.

By Method

The market is categorized into translation systems and transcription & translation systems. In 2022, the transcription & translation systems segment accounted for the highest revenue share due to the fact that by integrating both processes in a single tube configuration, coupled translation and transcription devices give researchers time-saving options for eukaryotic in vitro translation and transcription. Numerous applications of transcription and translation systems are found in low- to high-throughput functional proteome and genome investigations.

 By Application

The market is categorized into high throughput, protein-protein interaction, protein-labelling, enzyme engineering, and protein purification. In the global market, the segment accounted for the largest revenue share in 2022 owing to increasing demand of enzyme engineering method. Enzyme engineering has become increasingly essential in biomanufacturing, synthetic biology, and medicine as a result of its continued growth.

By End User

The market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, others. In 2022, the pharmaceutical & biotechnological companies segment accounted for the largest revenue share owing to growth of the current manufacturing capabilities for biopharmaceuticals. For instance, Takara Bio Inc. stated in February 2022 that its production facility, the Center for Gene and Cell Processing in Shiga, Japan, would be expanding. The development of the GMP facility will respond to the rising need for contract development and manufacturing firms. Additionally, it will meet the requirement for a wider range of raw materials and production techniques.

Regional Markets

In 2022, North America region accounted for the highest revenue in the cell-free protein expression market and is expected to maintain its dominance during the forecast period. This is attributed to expansion of the biotechnology and pharmaceutical sectors, technically advanced products, rise in the prevalence of diseases like cancer, and investments and funding in drug development research. For instance, Promega announced the opening of the newly built R&D center (Kornberg Center) on its site in Fitchburg, Wisconsin, in April 2021. In the areas of genetic identification, cellular and molecular biology, life science research, scientific applications, clinical diagnostics, and training, the facility can support crucial technology and product development. The Asia Pacific region is predicted to have the greatest growth rate due to strategic actions taken by important market participants. For instance, the Ehime Prefecture’s New Growth Manufacturing Company Comprehensive Support Program provided funds to the Japanese company CELLFREE SCIENCES CO., LTD in July 2021. To identify novel treatment approaches and drug targets, the company will leverage its own technologies, including a protein bead array platform.

Competitor Insights

Some of the key players operating in the cell-free protein expression market are Biotechrabbit GmbH, Takara Bio Company, CellFree Sciences Co., Ltd., Promega Corporation, New England Biolabs, Thermo Fisher Scientific, Inc., Jena Bioscience GmbH, GeneCopoeia, Inc., Cube Biotech GmbH, and Merck KGaA.

To increase their market position, major companies in this market are implementing a variety of organic and inorganic strategies, including alliances, mergers and acquisitions, geographic expansion, and strategic collaborations.

• For instance, Sutro Biopharma and Merck renewed their collaboration on cytokine derivative research in September 2021. According to the terms of the contract, Sutro and Merck are working together to conduct preclinical research and development on cytokine derivatives using Sutro’s unique site-specific conjugation and cell-free protein synthesis platforms, Xpress CF+ and XpressCF.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, method, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Cell-free Protein Expression Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Reagents
• Expression Systems
  • Wheat Germ Cell-free Protein Expression System
  • coli Cell-free Protein Expression System
  • Insect Cells Cell-free Protein Expression System
  • Human Cell-free Protein Expression System
  • Rabbit Reticulocytes Cell-free Protein Expression System
  • Others

Method (Revenue, USD Million), 2022 – 2033

• Translation Systems
• Transcription & Translation Systems

Application (Revenue, USD Million), 2022 – 2033

• High Throughput
• Protein-Protein Interaction
• Protein-Labelling
• Enzyme Engineering
• Protein Purification

End user (Revenue, USD Million), 2022 – 2033

• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA